Tau Biology and Tau-Directed Therapies for Alzheimer's Disease

Autor(en): Bakota, Lidia
Brandt, Roland 
Stichwörter: A-BETA; AGGREGATION INHIBITOR THERAPY; AMYLOID-BETA; COGNITIVE DEFICITS; DENDRITIC SPINE ALTERATIONS; MICROTUBULE-STABILIZING AGENT; PAIRED HELICAL FILAMENTS; PASSIVE-IMMUNIZATION; Pharmacology & Pharmacy; PROTEIN PHOSPHATASE 2A; Toxicology; TRANSGENIC MOUSE MODEL
Erscheinungsdatum: 2016
Herausgeber: ADIS INT LTD
Journal: DRUGS
Volumen: 76
Ausgabe: 3
Startseite: 301
Seitenende: 313
Zusammenfassung: 
Alzheimer's disease (AD) is characterised by a progressive loss of cognitive functions. Histopathologically, AD is defined by the presence of extracellular amyloid plaques containing Ab and intracellular neurofibrillary tangles composed of hyperphosphorylated tau proteins. According to the now well-accepted amyloid cascade hypothesis is the Ab pathology the primary driving force of AD pathogenesis, which then induces changes in tau protein leading to a neurodegenerative cascade during the progression of disease. Since many earlier drug trials aiming at preventing Ab pathology failed to demonstrate efficacy, tau and microtubules have come into focus as prominent downstream targets. The article aims to develop the current concept of the involvement of tau in the neurodegenerative triad of synaptic loss, cell death and dendritic simplification. The function of tau as a microtubule-associated protein and versatile interaction partner will then be introduced and the rationale and progress of current tau-directed therapy will be discussed in the biological context.
ISSN: 00126667
DOI: 10.1007/s40265-015-0529-0

Show full item record

Page view(s)

3
Last Week
0
Last month
0
checked on Mar 3, 2024

Google ScholarTM

Check

Altmetric